Initiator Pharma A/S Press release 2018-11-15



# Initiator Pharma announces that exercised warrants and directed share issue are now registered with the Danish Companies Registration Office

Initiator Pharma A/S ("Initiator Pharma") announced today, November 15, 2018, that the exercised series TO 1 warrants, whose subscription period ended on November 1, 2018, and the directed share issue, have now been registered with the Danish Companies Registration Office.

A total of 5.789.294 new shares have been registered, which means that the number of shares in Initiator Pharma after registration amounts to 23.157.178. The share capital amounts to 2.431.503,69 DKK. Conversion of interim shares to shares is expected to take place on November 20, 2018. Different agents may take a different amount of time to convert, which means that in some cases the shares may become available only after the above estimated date.

#### Financial advisor

Sedermera Fondkommission is the financial advisor and issuing agent to Initiator Pharma in connection with the exercise of warrants of series TO 1 and the directed share issue.

## For further information about the warrants of series TO 1, please contact:

Sedermera Fondkommission Telephone: +46 40-615 14 10 E-mail: info@sedermera.se

## For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035

E-mail: ceo@initiatorpharma.com

## **About Initiator Pharma**

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for the treatment of Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond or cannot be treated with the current marketed medication.

## **About Erectile dysfunction**

Erectile dysfunction is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fueled by aging demographics and increasing prevalence of life style diseases such as diabetes. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, and relationship problems (1,2,3).

- 1. Shabsigh R, et al. (1998) Increased incidence of depressive symptoms in men with erectile dysfunction. *Urology* 52(5):848–852.
- 2. Mccabe MP, Althof SE (2014) A systematic review of the psychosocial outcomes associated with erectile dysfunction: Does the impact of erectile dysfunction extend beyond a man's inability to have sex? *J Sex Med* 11(2):347–363.
- 3. Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors. Sex Med Rev 5(4):508–520.